<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178397</url>
  </required_header>
  <id_info>
    <org_study_id>FLARE /GFPC 03-2013</org_study_id>
    <nct_id>NCT02178397</nct_id>
  </id_info>
  <brief_title>A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR</brief_title>
  <acronym>FLARE</acronym>
  <official_title>A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current first line treatment of patients with EGFR activating mutation lung cancer is
      EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of
      response rate and progression-free survival. However, an acquired resistance occurs almost
      constantly. The second-line treatment includes platinum-based chemotherapy in the absence of
      contraindication. This chemotherapy is then administered after discontinuing EGFR TKIs.

      However, a rebound phenomenon of the disease was described in patients who discontinued EGFR
      TKIs. Some clinical teams therefore recommend, as a precaution, in order to avoid any
      withdrawal phenomenon, to never discontinue EGFR TKIs in patients developing an EGFR TKI
      acquired resistance.

      It seems therefore useful to conduct a study to better define the therapeutic strategy to
      adopt in patients developing an acquired resistance after having received EGFR TKIs as first
      line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy by PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression evaluated every 6-9 weeks</time_frame>
    <description>Efficacy will be assessed by the PFS, define as time between randomization of the patient in the study and disease progression (local, regional, distant and second cancer) or death (all causes). Alive patients free of progression will be censored at the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>scores of QoL</measure>
    <time_frame>at 4 months after inclusion</time_frame>
    <description>difference between the scores of QoL at baseline and at 4 months after inclusion for the three targeted dimensions of EORTC QLQ-C30 (global quality of life, fatigue and physical functioning). A difference or 10 points or more at 4 months after inclusion for one score between the 2 arms will be considered as clinically relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Overall survival defined as time interval between randomization and death (all causes). Alive patients will be censored at the last date of news or data cut off</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral response</measure>
    <time_frame>every 6-9 weeks</time_frame>
    <description>Tumoral response (complete response, partial response, stable disease, progression) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>From date of randomization until study participation, assessed up to 100 months</time_frame>
    <description>Toxicities according to NCI-CTC-AE v.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebound phenomenon (flare)</measure>
    <time_frame>within 3 weeks after disease progression before inclusion</time_frame>
    <description>Rebound phenomenon (flare) defined by a hospitalization or a death within 3 weeks for disease progression after the end of TKI EGFR treatment (in the arm without EGFR TKI) and date of onset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>NSCLC Patients With EGFR Activating Mutation</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION chemotherapy: 4 cycles of
pemetrexed with cisplatin or carboplatin
or gemcitabine with cisplatin or carboplatin in combination with erlotinib
THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STANDARD ARM A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INDUCTION chemotherapy: 4 cycles of
pemetrexed with cisplatin or carboplatin
or gemcitabine with cisplatin or carboplatin
THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERLOTINIB WITH CHEMOTHERAPY</intervention_name>
    <arm_group_label>EXPERIMENTAL ARM B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHEMOTHERAPY ONLY</intervention_name>
    <arm_group_label>STANDARD ARM A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged 18 years or more

          -  Non-small cell lung cancer carcinoma (NSCLC) cytologically or histologically confirmed

          -  Measurable disease according to RECIST 1.1 criteria

          -  Life expectancy greater than 12 weeks

          -  Performance Status (ECOG) ≤ 2

          -  Stage IIIB considered ineligible for thoracic radiotherapy at &quot;curative&quot; doses or
             stage IV

          -  Presence of at least one measurable target lesion

          -  Documented disease progression (RECIST 1.1) after first line treatment with erlotinib,
             during at least 4 months in case of partial or complete response according to RECIST
             criteria, or 6 months in case of stable disease. The treatment with Erlotinib should
             not be discontinued for more than 8 days between the progression and the inclusion in
             the study. The daily dose of Erlotinib should be at least 50 mg.

          -  Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or
             L858R, G719X or L861Q)

          -  One additional line of previous chemotherapy is allowed if administered in adjuvant or
             neoadjuvant setting and received more than six months before.

          -  Prior radiotherapy is allowed if the volume of irradiated marrow is &lt;25% of the total
             bone marrow. The prior radiotherapy must be completed at least two weeks before study
             entry

          -  Brain metastases are allowed if they are controlled without steroids and if their
             treatment is completed (radiotherapy and/or surgery). Patients with no symptomatic
             brain metastases may be included; even if brain metastases are progressive and even if
             they are the only site of progression (since the investigator considers that
             irradiation is not required). These metastases have not to be life-threatening (are
             excluded: cerebellar metastasis ≥ 2 cm, brainstem metastasis, brain metastasis &gt; 3 cm
             and/or near important functional structure).

          -  Normal Liver function (bilirubin ≤ULN, AST - ALT ≤2.5 x ULN, alkaline phosphatase ≤3 x
             ULN), or in case of liver metastases: alkaline phosphatase, AST-ALT ≤ 5 x ULN

          -  Normal renal function: blood creatinine ≤ULN and / or creatinine clearance&gt; 60 ml/min
             calculated with the MDRD formula

          -  Normal blood function: absolute neutrophil count ≥ 1.5 x 109/l and / or platelets ≥
             100 x 109 / l, hemoglobin&gt; 9 g/dl

          -  Woman and man under efficient contraception during treatment and at least 6 months
             after the end of treatment by pemetrexed or platinum or gemcitabine

          -  Signed written Informed consent

        Exclusion Criteria:

          -  Bronchoalveolar, mixed, neuroendocrine and small cell lung cancers

          -  Patient with only bone metastases are not eligible

          -  All progressive metastatic sites treated locally (surgery, radiotherapy)

          -  Superior vena cava syndrome

          -  Uncontrolled cardiac disease requiring treatment

          -  Congestive heart failure, angina pectoris, significant arrhythmias or history of
             myocardial infarction within the previous 12 months

          -  Neurological or psychiatric disorders

          -  Uncontrolled infectious disease

          -  Peripheral neuropathy grade≥ 2

          -  Definitive contraindication for the use of steroids

          -  Inductive anti-epileptic treatments (phenobarbital, phenytoïne)• Previous or
             concomitant other cancer, including skin cancer (except basal cell cancer of the
             skin), except in situ treated carcinoma of the cervix , except cancer treated with
             surgery alone without recurrence for 5 years

          -  Pregnant or breastfeeding woman

          -  Patient follow-up not achievable

          -  Participation in a trial within the last 30 days

          -  Patient deprived of liberty as a result of a justice or administrative decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radj GERVAIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse - CAEN- FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Aix En Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIC</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Draguignan</city>
        <zip>83007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIC</name>
      <address>
        <city>GAP</city>
        <zip>05007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch La Roche/Yon</name>
      <address>
        <city>La Roche/yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Le MANS</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Longjumeau</city>
        <zip>91160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Lorient</city>
        <zip>35632</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Macon</city>
        <zip>71018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78201</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Meulan</city>
        <zip>78250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>PAU</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Salon de Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Sens</city>
        <zip>89100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>St BRIEUC</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>St ETIENNE</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Tarbes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des Armées Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Villefranche</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>lung cancer</keyword>
  <keyword>EGFR mutation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

